To study the relative contributions of parasympathetic and sympathetic mechanisms in airway obstruction in patients with emphysema, we gave supramaximal doses of anticholinergic and adrenergic agents in sequence and in combination. Serial doses of one agent were administered to achieve a plateau of bronchodilatation; after that the other agent was administered. The plateau achieved with the anticholinergic agent (atropine methonitrate) was significantly higher than that achieved with the adrenergic agent (salbutamol). When the adrenergic agent was given first, additional bronchodilatation was achieved with subsequent use of the anticholinergic agent. When the anticholinergic agent was given first, no additional bronchodilatation was achieved with subsequent administration of the adrenergic agent. When both agents were given simultaneously, the degree of bronchodilatation was virtually identical to that obtained with the anticholinergic agent alone. Tests sensitive to small-airway and large-airway function and lung volumes gave essentially the same results. Thus, all achievable bronchodilatation was obtained with the anticholinergic agent alone. These results suggest that the two classes of agents produce bronchodilatation through a common cholinergic pathway in emphysema, and support the concept that parasympathetic activity is the dominant reversible component of airway obstruction in this disease.
This article has been cited by other articles:
Hanania, N. A., Donohue, J. F.
(2007). Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators. Proc Am Thorac Soc
4: 526-534
[Abstract][Full Text]
Bos, I. S. T., Gosens, R., Zuidhof, A. B., Schaafsma, D., Halayko, A. J., Meurs, H., Zaagsma, J.
(2007). Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J
30: 653-661
[Abstract][Full Text]
Brusasco, V.
(2006). Reducing cholinergic constriction: the major reversible mechanism in COPD. ERR
15: 32-36
[Abstract][Full Text]
Belmonte, K. E.
(2005). Cholinergic Pathways in the Lungs and Anticholinergic Therapy for Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc
2: 297-304
[Abstract][Full Text]
Vincken, W.
(2005). Bronchodilator treatment of stable COPD: long-acting anticholinergics. ERR
14: 23-31
[Abstract][Full Text]
Sirak, T. E., Jelic, S., Le Jemtel, T. H.
(2004). Therapeutic update: Non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol
44: 497-502
[Abstract][Full Text]
Donohue, J. F., van Noord, J. A., Bateman, E. D., Langley, S. J., Lee, A., Witek, T. J. Jr, Kesten, S., Towse, L.
(2002). A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol*. Chest
122: 47-55
[Abstract][Full Text]
Vincken, W., van Noord, J.A., Greefhorst, A.P.M., Bantje, Th.A., Kesten, S., Korducki, L., Cornelissen, P.J.G.
(2002). Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J
19: 209-216
[Abstract][Full Text]
Hadcroft, J, Calverley, P M A
(2001). Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax
56: 713-720
[Abstract][Full Text]
Calverley, P.M.A.
(2001). Modern treatment of chronic obstructive pulmonary disease. Eur Respir J
18: 60S-66s
[Abstract][Full Text]
D'Urzo, A. D., De Salvo, M. C., Ramirez-Rivera, A., Almeida, J., Sichletidis, L., Rapatz, G., Kottakis, J.
(2001). In Patients With COPD, Treatment With a Combination of Formoterol and Ipratropium Is More Effective Than a Combination of Salbutamol and Ipratropium : A 3-Week, Randomized, Double-Blind, Within-Patient, Multicenter Study. Chest
119: 1347-1356
[Abstract][Full Text]
ON, L. S., BOONYONGSUNCHAI, P., WEBB, S., DAVIES, L., CALVERLEY, P. M. A., COSTELLO, R. W.
(2001). Function of Pulmonary Neuronal M2 Muscarinic Receptors in Stable Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med.
163: 1320-1325
[Abstract][Full Text]
COOK, D., GUYATT, G., WONG, E., GOLDSTEIN, R., BEDARD, M., AUSTIN, P., RAMSDALE, H., JAESCHKE, R., SEARS, M.
(2001). Regular Versus As-Needed Short-Acting Inhaled {beta}-Agonist Therapy for Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med.
163: 85-90
[Abstract][Full Text]
Davies, L., Nisar, M., Pearson, M.G., Costello, R.W., Earis, J.E., Calverley, P.M.A.
(1999). Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease. QJM
92: 395-400
[Abstract][Full Text]
Sato, E., Koyama, S., Okubo, Y., Kubo, K., Sekiguchi, M.
(1998). Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am. J. Physiol. Lung Cell. Mol. Physiol.
274: L970-L979
[Abstract][Full Text]
DeYoung, G. R., Vetter, P. L., Kradjan, W. A.
(1992). The Pharmacological Treatment of Ambulatory Chronic Obstructive Pulmonary Disease Patients. Journal of Pharmacy Practice
5: 204-216
[Abstract]
